Literature DB >> 16383229

Autoaggressive immune-mediated movement disorders.

Davide Martino1, Gavin Giovannoni.   

Abstract

Poststreptococcal disorders exhibit a remarkable comorbidity of neurologic and psychiatric features. A similar combination of symptoms is also described in other conditions, such as connective tissue or paraneoplastic disorders, albeit less frequently. A better understanding of the underlying mechanisms associated with autoaggressive immune-mediated attack on the basal ganglia is required. This understanding will ideally aid clinicians in diagnosing these conditions and lead to appropriate clinical trials, for example, of chemoprophylaxis strategies to prevent recurrent streptococcal infection and of the use of immunosuppressive treatments.

Entities:  

Mesh:

Year:  2005        PMID: 16383229

Source DB:  PubMed          Journal:  Adv Neurol        ISSN: 0091-3952


  4 in total

1.  Protein array profiling of tic patient sera reveals a broad range and enhanced immune response against Group A Streptococcus antigens.

Authors:  Mauro Bombaci; Renata Grifantini; Marirosa Mora; Valerio Reguzzi; Roberto Petracca; Eva Meoni; Sergio Balloni; Chiara Zingaretti; Fabiana Falugi; Andrea G O Manetti; Immaculada Margarit; James M Musser; Francesco Cardona; Graziella Orefici; Guido Grandi; Giuliano Bensi
Journal:  PLoS One       Date:  2009-07-22       Impact factor: 3.240

2.  Age-related gene expression in Tourette syndrome.

Authors:  Lisa Lit; Amanda Enstrom; Frank R Sharp; Donald L Gilbert
Journal:  J Psychiatr Res       Date:  2008-05-15       Impact factor: 4.791

Review 3.  Cranial movement disorders: clinical features, pathophysiology, differential diagnosis and treatment.

Authors:  Giovanni Fabbrini; Giovanni Defazio; Carlo Colosimo; Philip D Thompson; Alfredo Berardelli
Journal:  Nat Clin Pract Neurol       Date:  2009-02

Review 4.  Tourette's syndrome: clinical features, pathophysiology, and therapeutic approaches.

Authors:  Norbert Müller
Journal:  Dialogues Clin Neurosci       Date:  2007       Impact factor: 5.986

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.